A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer compared to standard treatments by checking whether it makes cancers smaller or disappear completely and if it helps participants live longer. The study also assesses whether Mo-Rez in combination with bevacizumab is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of Mo-Rez.

NCT Number	NCT07684612
Lead Sponsor	GlaxoSmithKline Collaborators: GOG, ENGOT, APGOT
Conditions	Ovarian Neoplasms
Enrollment	690 participants
Start Date	2026-09-22
Primary Completion	2030-05-21 (estimated)
Study Completion	2033-04-22 (estimated)
Updated on ClinicalTrials.gov	2026-07-15